文献速递前列腺癌

前列腺癌的前列腺特异性膜抗原靶向治疗:旨在改善治疗结局

Prostate-Specific Membrane Antigen-Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes.
PubMed 文献 · Eur Urol · 2023-12-16

本文综述前列腺特异性膜抗原(PSMA)靶向治疗的研究进展,检索PubMed及美国临床肿瘤学会、欧洲肿瘤内科学会年会摘要至2023年9月。PSMA靶向治疗疗效受PSMA表达异质性限制,理解PSMA调控机制(HOXB13正向、雄激素受体负向调控及表观遗传调控)有助于上调PSMA表达并设计协同联合方案。

要点

  • PSMA在多数前列腺癌中过表达,是靶向治疗的热门靶点。
  • PSMA靶向治疗疗效受患者间及瘤内/瘤间PSMA表达异质性限制。
  • HOXB13和雄激素受体分别正向和负向调控PSMA表达。

核心结论

  • PSMA靶向治疗进展迅速,但其疗效受靶点表达异质性强烈限制。
  • 全面理解PSMA调控机制有助于通过增加PSMA表达改善疗效,并为协同联合治疗提供基础。

研究设计与样本

  • 本文为叙述性综述,通过PubMed进行详细文献检索,并回顾了截至2023年9月的美国临床肿瘤学会和欧洲肿瘤内科学会年会摘要。

主要发现

  • PSMA靶向治疗结局强烈依赖于细胞表面PSMA表达水平。
  • PSMA在不同层面(患者间和瘤内/瘤间)的异质性限制了PSMA靶向治疗的疗效。
  • HOXB13和雄激素受体已被确定为分别正向和负向调控PSMA表达的关键转录因子。
  • 近期已报道PSMA的表观遗传调控。
  • 许多已确立的治疗方法具有上调PSMA水平以及增强当前放射性配体介导的DNA损伤的潜力。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein overexpressed in most prostate cancers and exploited as a target for PSMA-targeted therapies. Different approaches to target PSMA-expressing cancer cells have been developed, showing promising results in clinical trials. OBJECTIVE: To discuss the regulation of PSMA expression and the main PSMA-targeted therapeutic concepts illustrating their clinical development and rationalizing combination approaches with examples. EVIDENCE ACQUISITION: We performed a detailed literature search using PubMed and reviewed the American Society of Clinical Oncology and European Society of Medical Oncology annual meeting abstracts up to September 2023. EVIDENCE SYNTHESIS: We present an overarching description of the different strategies to target PSMA. The outcomes of PSMA-targeted therapies strongly rely on surface-bound PSMA expression. However, PSMA heterogeneity at different levels (interpatient and inter/intratumoral) limits the efficacy of PSMA-targeted therapies. We highlight the molecular mechanisms governing PSMA regulation, the understanding of which is crucial to designing therapeutic strategies aimed at upregulating PSMA expression. Thus far, homeobox B13 (HOXB13) and androgen receptor (AR) have emerged as critical transcription factors positively and negatively regulating PSMA expression, respectively. Furthermore, epigenetic regulation of PSMA has been also reported recently. In addition, many established therapeutic approaches harbor the potential to upregulate PSMA levels as well as potentiate DNA damage mediated by current radioligands. CONCLUSIONS: PSMA-targeted therapies are rapidly advancing, but their efficacy is strongly limited by the heterogeneous expression of the target. A thorough comprehension of how PSMA is regulated will help improve the outcomes through increasing PSMA expression and will provide the basis for synergistic combination therapies. PATIENT SUMMARY: Prostate-specific membrane antigen (PSMA) is overexpressed in most prostate cancers. PSMA-targeted therapies have shown promising results, but the heterogeneous expression of PSMA limits their efficacy. We propose to better elucidate the regulation of PSMA expression to increase the levels of the target and improve the therapeutic outcomes.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Corpetti M, Müller C, Beltran H, et al. Prostate-Specific Membrane Antigen-Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes. Eur Urol. 2023. PMID: 38104015. doi:10.1016/j.eururo.2023.11.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。